Blog
RSS FeedPosted by Michael Wonder on 10 Jan 2019
Decision to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
10 January 2019 - PHARMAC is pleased to announce its decision to approve a multi-product agreement with Merck Sharpe & ...
Posted by Michael Wonder on 20 Dec 2018
Decisions relating to the funded brands of some anti-retroviral treatments for HIV
20 December 2018 - PHARMAC is pleased to announce decisions to award sole supply for seven anti-retroviral treatments used in ...
Posted by Michael Wonder on 17 Dec 2018
PHARMAC funding decision gives Kiwis with hepatitis C access to a potential cure
17 December 2018 - Life changing treatment for New Zealanders living with hepatitis C will be available from 1 February ...
Posted by Michael Wonder on 17 Dec 2018
Decision to fund a new hepatitis C treatment (Maviret) and to widen access to adalimumab (Humira) for psoriasis
17 December 2018 - PHARMAC is pleased to announce a decision to fund a new treatment for chronic hepatitis C ...
Posted by Michael Wonder on 14 Dec 2018
Decision in relation to infliximab, tocilizumab and rituximab
14 December 2018 - PHARMAC is pleased to announce a decision on how three hospital medicines (infliximab, tocilizumab and rituximab) ...
Posted by Michael Wonder on 12 Dec 2018
Health organisations join calls for a review into government drug buying agency
12 December 2018 - Pressure is mounting on the government to announce a review into its drug buying agency with ...
Posted by Michael Wonder on 30 Nov 2018
Proposal involving treatments for multiple sclerosis, narcolepsy and attention deficit hyperactivity disorder
30 November 2018 - PHARMAC is seeking feedback on a proposal involving the following products through a provisional agreement with ...
Posted by Michael Wonder on 30 Oct 2018
Proposal to change how discarded medicines are reimbursed
30 October 2018 - PHARMAC is seeking feedback on a proposal to change how the agency reimburses discarded medicines in ...
Posted by Michael Wonder on 28 Oct 2018
Update on proposal to move to one funded brand of lamotrigine (Logem)
26 October 2018 - PHARMAC would like to thank everyone who provided feedback on a proposal to move to one ...
Posted by Michael Wonder on 28 Oct 2018
Calls for PHARMAC review after funds made available to offset wage settlements
24 October 2018 - A request that the government's drug-buying agency be reviewed has opposition support with claims money is ...
Posted by Michael Wonder on 14 Oct 2018
New diabetes medicine funded by PHARMAC not what the doctors ordered
15 October 2018 - As of October, PHARMAC is funding a new Type 2 diabetes medicine called vildagliptin. ...
Posted by Michael Wonder on 09 Oct 2018
Evidence-based approach to funding choices more important than ever
10 October 2018 - Cancer will affect almost all New Zealanders at some point in their lives. Given the range ...
Posted by Michael Wonder on 09 Oct 2018
Outdated public funding model failing New Zealand patients
9 October 2018 - Publicly funded modern medicines are out of reach for many patients in New Zealand according to ...
Posted by Michael Wonder on 28 Sep 2018
Decision to fund sapropterin
28 September 2018 - PHARMAC is pleased to announce a decision to list sapropterin (Kuvan), a treatment for the rare ...
Posted by Michael Wonder on 26 Sep 2018
PHARMAC urged to subsidise cost prohibitive but 'highly effective' contraceptive option
26 September 2018 - The Mirena is a popular and effective contraceptive option but it's $340 price tag has been ...